Should I buy or sell OraSure Technologies stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OSUR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OSUR, but not buy additional shares or sell existing shares. View OSUR analyst ratings or view top-rated stocks .

What is OraSure Technologies' stock price target for 2024?

3 Wall Street research analysts have issued 12 month price targets for OraSure Technologies' stock. Their OSUR share price targets range from $5.00 to $9.00. On average, they expect the company's stock price to reach $6.38 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price. View analysts price targets for OSUR or view top-rated stocks among Wall Street analysts .

How have OSUR shares performed in 2024?

OraSure Technologies' stock was trading at $8.20 at the beginning of the year. Since then, OSUR shares have decreased by 35.6% and is now trading at $5.28. View the best growth stocks for 2024 here .

Are investors shorting OraSure Technologies?

OraSure Technologies saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 2,960,000 shares, a decrease of 29.2% from the March 15th total of 4,180,000 shares. Based on an average daily volume of 936,100 shares, the short-interest ratio is currently 3.2 days. Currently, 4.2% of the company's stock are sold short. View OraSure Technologies' Short Interest .

When is OraSure Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our OSUR earnings forecast .

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) announced its quarterly earnings data on Tuesday, February, 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.13 by $0.09. The medical instruments supplier had revenue of $75.88 million for the quarter, compared to the consensus estimate of $74.13 million. OraSure Technologies had a trailing twelve-month return on equity of 14.50% and a net margin of 13.23%. The business's revenue for the quarter was down 38.3% on a year-over-year basis. During the same quarter last year, the company posted $0.21 earnings per share.

What ETFs hold OraSure Technologies' stock?

ETFs with the largest weight of OraSure Technologies (NASDAQ:OSUR) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Amplify Treatments, Testing and Advancements ETF (GERM) . Hartford Multifactor Small Cap ETF (ROSC) .

What guidance has OraSure Technologies issued on next quarter's earnings?

OraSure Technologies updated its first quarter 2024 earnings guidance on Wednesday, April, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50.0 million-$54.0 million, compared to the consensus revenue estimate of $52.1 million.

What is Stephen Tang's approval rating as OraSure Technologies' CEO?

2 employees have rated OraSure Technologies Chief Executive Officer Stephen Tang on Glassdoor.com . Stephen Tang has an approval rating of 100% among the company's employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI) , Citigroup (C) , Energy Transfer (ET) , XOMA (XOMA) , Overstock.com (OSTK) , Ford Motor (F) , Pfizer (PFE) , Abbott Laboratories (ABT) , Advanced Micro Devices (AMD) and Activision Blizzard (ATVI) .

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.45%) and Counterpoint Mutual Funds LLC (0.03%). Insiders that own company stock include Kathleen Gallagher Weber, Michael Celano, Nancy J Gagliano and Ronny B Lancaster. View institutional ownership trends .

How do I buy shares of OraSure Technologies?

Shares of OSUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OSUR

OraSure Technologies (OSUR) Stock Price, News & Analysis

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)

Free OSUR Stock Alerts

$5.28

+0.03 (+0.57%)

(As of 01:37 PM ET)

Compare

Today's Range: $5.20
▼
$5.33
50-Day Range: $5.22
▼
$7.73
52-Week Range: $4.38
▼
$8.45

Volume: 184,309 shs
Average Volume: 894,542 shs
Market Capitalization: $403.97 million

P/E Ratio: 7.33
Dividend Yield: N/A
Price Target: $6.38

Get OraSure Technologies alerts:

OraSure Technologies MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 20.7% Upside
$6.38 Price Target
Short Interest: Healthy
4.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.09
Upright™ Environmental Score
News Sentiment: 0.15
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.11) to ($0.15) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.09 out of 5 stars

Medical Sector

166th out of 914 stocks

Surgical & Medical Instruments Industry

24th out of 94 stocks

2.2

Analyst's Opinion

Consensus Rating
OraSure Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
OraSure Technologies has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
4.21% of the float of OraSure Technologies has been sold short.
Short Interest Ratio / Days to Cover
OraSure Technologies has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in OraSure Technologies has recently decreased by 29.19%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
OraSure Technologies does not currently pay a dividend.
Dividend Growth
OraSure Technologies does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
OraSure Technologies has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Respiratory tract infection tests" products. See details.
Environmental Sustainability
The Environmental Impact score for OraSure Technologies is -1.09.

2.3

News and Social Media Coverage

News Sentiment
OraSure Technologies has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for OraSure Technologies this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added OraSure Technologies to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OraSure Technologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.40% of the stock of OraSure Technologies is held by insiders.
Percentage Held by Institutions
93.50% of the stock of OraSure Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for OraSure Technologies are expected to decrease in the coming year, from ($0.11) to ($0.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OraSure Technologies is 7.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.69.
Price to Earnings Ratio vs. Sector
The P/E ratio of OraSure Technologies is 7.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 206.33.
Price to Book Value per Share Ratio
OraSure Technologies has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad GoldenCrest Metals

Emergency: Biden's $20 Trillion Mistake Could Cost YOU!

The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.

Learn More Now

About OraSure Technologies Stock (NASDAQ:OSUR)

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

OSUR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OSUR Stock News Headlines

April 14, 2024 | investing.com

OraSure reports data breach, says impact contained

April 12, 2024 | marketwatch.com

OraSure Technologies Hit With Cybersecurity Breach

April 18, 2024 | GoldenCrest Metals (Ad)

Emergency: Biden's $20 Trillion Mistake Could Cost YOU!

The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.

April 12, 2024 | msn.com

OraSure reports cybersecurity breach, says incident has been contained

April 11, 2024 | americanbankingnews.com

OraSure Technologies (NASDAQ:OSUR) & Carmell (NASDAQ:CTCX) Critical Survey

March 29, 2024 | finance.yahoo.com

OraSure Technologies, Inc. (OSUR)

March 28, 2024 | sg.finance.yahoo.com

Singapore's DBS bank confident of 15%-17% ROE in next 3-5 years, CEO says

March 28, 2024 | finance.yahoo.com

OraSure Technologies, Inc.'s (NASDAQ:OSUR) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

April 18, 2024 | GoldenCrest Metals (Ad)

Emergency: Biden's $20 Trillion Mistake Could Cost YOU!

The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.

March 21, 2024 | finance.yahoo.com

NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

March 16, 2024 | finance.yahoo.com

OSUR Oct 2024 10.000 call

March 16, 2024 | finance.yahoo.com

OSUR Jul 2024 5.000 put

March 1, 2024 | finance.yahoo.com

OraSure Technologies Full Year 2023 Earnings: EPS Beats Expectations

February 28, 2024 | finance.yahoo.com

OraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2023 Earnings Call Transcript

February 28, 2024 | finance.yahoo.com

Q4 2023 OraSure Technologies Inc Earnings Call

February 27, 2024 | benzinga.com

OraSure Technologies: Q4 Earnings Insights

February 27, 2024 | msn.com

OraSure Technologies Non-GAAP EPS of $0.22 beats by $0.11, revenue of $75.88M beats by $1.61M

February 27, 2024 | finance.yahoo.com

OraSure Technologies Inc (OSUR) Reports Q4 Revenue Decline Amidst Strategic Growth Efforts

February 27, 2024 | globenewswire.com

OraSure Reports Q4 ‘23 Revenue of $75.9 Million

February 26, 2024 | benzinga.com

Preview: OraSure Technologies's Earnings

February 17, 2024 | finance.yahoo.com

OSUR Mar 2024 10.000 put

February 16, 2024 | money.usnews.com

Orasure Technologies Inc.

February 13, 2024 | finance.yahoo.com

OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th

February 9, 2024 | finance.yahoo.com

3 Strong Buy Stocks Under $10: January 2024

January 31, 2024 | morningstar.com

OraSure Technologies Inc OSUR

January 4, 2024 | finance.yahoo.com

OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company

December 22, 2023 | finance.yahoo.com

Insider Sell: Chief Product Officer Kathleen Weber Sells 24,129 Shares of OraSure Technologies Inc

See More Headlines

Receive OSUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OraSure Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Supplies
Current Symbol: NASDAQ:OSUR
CUSIP: 68554V10
CIK: 1116463
Web: www.orasure.com
Phone: (610) 882-1820
Fax: 610-882-1830
Employees: 638
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.38
High Stock Price Target: $9.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +21.4%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.72
Trailing P/E Ratio: 7.29
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $53.65 million
Net Margins: 13.23%
Pretax Margin: 13.88%
Return on Equity: 14.50%
Return on Assets: 12.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.77
Quick Ratio: 8.57

Sales & Book Value

Annual Sales: $405.47 million
Price / Sales: 0.99
Cash Flow: $1.30 per share
Price / Cash Flow: 4.04
Book Value: $5.86 per share
Price / Book: 0.90

Miscellaneous

Outstanding Shares: 76,510,000
Free Float: 73,909,000
Market Cap: $401.68 million
Optionable: Optionable
Beta: 0.15

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Ms. Carrie Eglinton Manner (Age 49)
President, CEO & Director
Comp: $1.42M
Mr. Kenneth J. McGrath (Age 51)
Chief Financial Officer
Comp: $701.58k
Ms. Kathleen Gallagher Weber (Age 57)
Chief Product Officer
Comp: $890.87k
Ms. Michele Anthony (Age 49)
Senior VP, Chief Accounting Officer, Controller & Assistant Secretary
Mr. Rafal Iwasiow Ph.D.
Vice President of Science, Innovation & Technology
Mr. Jason Michael Plagman
Vice President of Investor Relations
Mr. Stefano Taucer
General Counsel & Corporate Secretary
Mr. David A. Rappaport C.F.A.
Senior Vice President Corporate Development, Strategy & Integration
Amy Steigerwalt
Senior Vice President of Human Resources
Mr. Zachary Wert
Senior Vice President of Global Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OSUR Stock Analysis - Frequently Asked Questions

Should I buy or sell OraSure Technologies stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OSUR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OSUR, but not buy additional shares or sell existing shares.
View OSUR analyst ratings or view top-rated stocks.
What is OraSure Technologies' stock price target for 2024?: 3 Wall Street research analysts have issued 12 month price targets for OraSure Technologies' stock. Their OSUR share price targets range from $5.00 to $9.00. On average, they expect the company's stock price to reach $6.38 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price.
View analysts price targets for OSUR or view top-rated stocks among Wall Street analysts.
How have OSUR shares performed in 2024?: OraSure Technologies' stock was trading at $8.20 at the beginning of the year. Since then, OSUR shares have decreased by 35.6% and is now trading at $5.28.
View the best growth stocks for 2024 here.
Are investors shorting OraSure Technologies?: OraSure Technologies saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 2,960,000 shares, a decrease of 29.2% from the March 15th total of 4,180,000 shares. Based on an average daily volume of 936,100 shares, the short-interest ratio is currently 3.2 days. Currently, 4.2% of the company's stock are sold short.
View OraSure Technologies' Short Interest.
When is OraSure Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our OSUR earnings forecast.
How were OraSure Technologies' earnings last quarter?: OraSure Technologies, Inc. (NASDAQ:OSUR) announced its quarterly earnings data on Tuesday, February, 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.13 by $0.09. The medical instruments supplier had revenue of $75.88 million for the quarter, compared to the consensus estimate of $74.13 million. OraSure Technologies had a trailing twelve-month return on equity of 14.50% and a net margin of 13.23%. The business's revenue for the quarter was down 38.3% on a year-over-year basis. During the same quarter last year, the company posted $0.21 earnings per share.

What ETFs hold OraSure Technologies' stock?: ETFs with the largest weight of OraSure Technologies (NASDAQ:OSUR) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Amplify Treatments, Testing and Advancements ETF (GERM).Hartford Multifactor Small Cap ETF (ROSC).
What guidance has OraSure Technologies issued on next quarter's earnings?: OraSure Technologies updated its first quarter 2024 earnings guidance on Wednesday, April, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50.0 million-$54.0 million, compared to the consensus revenue estimate of $52.1 million.
What is Stephen Tang's approval rating as OraSure Technologies' CEO?: 2 employees have rated OraSure Technologies Chief Executive Officer Stephen Tang on Glassdoor.com. Stephen Tang has an approval rating of 100% among the company's employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of OraSure Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), Overstock.com (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).
Who are OraSure Technologies' major shareholders?: OraSure Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.45%) and Counterpoint Mutual Funds LLC (0.03%). Insiders that own company stock include Kathleen Gallagher Weber, Michael Celano, Nancy J Gagliano and Ronny B Lancaster.
View institutional ownership trends.
How do I buy shares of OraSure Technologies?: Shares of OSUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OSUR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

OraSure Technologies (OSUR) Stock Price, News & Analysis

OraSure Technologies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About OraSure Technologies Stock (NASDAQ:OSUR)

OSUR Stock Price History

OSUR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OSUR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™